Agendia: New labs in Amsterdam

Last month Agendia announced the official opening of the company's new headquarters at Amsterdam's Science Park. The new facilities offer 13,000 square feet of laboratory and office space to support the company's molecular diagnostic cancer testing services and research activities.

“Agendia has a distinguished history of providing exceptional high quality diagnostic testing services that provide valuable information for cancer patients and the physicians who treat them," said Dr. Bernhard Sixt, Agendia’s president & chief executive officer (CEO). "The expanded capacity of our laboratories at our new location will allow us to meet the growing worldwide demand for our clinical services as we expand into major markets, enhancing the company's ability to serve the healthcare community."

Currently, Agendia offers three test services through its expanded laboratories, including MammaPrint, based on the Amsterdam 70-gene profile, that indicates risk of recurrence for breast cancer tumors and the first in vitro diagnostic multi-variant index assay (IVDMIA) cleared by the U.S. Food and Drug Administration (FDA), and CupPrint*, which identifies the origin of metastases with unknown primary tumors (Cancer of Unknown Primary).

“This move proves our ability to replicate our FDA-cleared and CLIA-certified laboratory in a new location in just four months,” said Dr. Jan Groen, vice president and chief operating officer (COO) at Agendia. “The increased laboratory space will also allow the company to expand our research and product development capabilities to enhance commercialization of emerging diagnostic discoveries in cancer."

20.07.2008